Viridian Therapeutics Inc. (VRDN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.80 (+2.18% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VRDN ranks #470 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.87B) and NRIX (Nurix Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $2.96B). Among the 5-stock peer group, VRDN leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).
Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $0 in revenue, -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.2% realized swing band)
FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 69.8 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While VRDN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.66) and Max Pain ($26.04) forces dealer call-delta covering toward $36.00.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Viridian Therapeutics Inc. (VRDN) surged +2.18% to $24.80, trading at 55% of its 52-week range ($13.18 – $34.29). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion
WALTHAM, Mass., October 20, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare di
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VRDN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VRDN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Viridian Therapeutics Inc. (VRDN) ranks #470 by composite RQD confidence (45/100, grade D) and #213 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, VRDN leads on earnings valuation at N/A trailing P/E, while MBX leads on capital efficiency and profitability with -26.4% ROIC and — gross margin. VCRE currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with VRDN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VRDN
ACTIVE
Viridian Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +2.18% | $2.81B | Benchmark Subject |
| VCRE Vicore Pharma Holding AB | C- | 61/100 | — | — | — | +4.56% | $2.87B | /vcre-vs-vrdn → |
| NRIX Nurix Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.51% | $2.96B | /nrix-vs-vrdn → |
| MBX MBX Biosciences Inc. | D | 44/100 | — | — | -26.4% | +0.70% | $2.63B | /mbx-vs-vrdn → |
| ZLAB Zai Lab Limited | E | 26/100 | — | 58.3% | -35.0% | -2.95% | $2.51B | /zlab-vs-vrdn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$342.6M, operating cash flow of -$276.4M, and free cash flow of -$276.9M (-18.9% YoY). On the balance sheet, VRDN closed FY2025 with $899.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$342.6M | -$276.4M | -$276.9M | $899.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$269.9M | -$232.3M | -$232.8M | $742.4M | $20.6M |
| FY2023 (FY) | 2023-12-31 | $0 | -$237.7M | -$184.2M | -$184.2M | — | — |
As of 2026-11-01, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.80 (+2.18% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VRDN ranks #470 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.87B) and NRIX (Nurix Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $2.96B). Among the 5-stock peer group, VRDN leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).
Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $0 in revenue, -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VRDN last traded at $24.80 (+2.18% on volume of 1,907,043 shares), positioning the stock +14.50% above its 50-day simple moving average ($21.66) and +13.97% above its 200-day simple moving average ($21.76). Across its 52-week range of $13.18 to $34.29, VRDN sits at the 55.0% percentile with a 14-day RSI of 69.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.2% ($22.27 to $27.33).
Why VRDN Stock surged +2.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.